Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast

Authors: Ahoua Benjamin Effi, Nguiessan Alphonse Aman, Baumaney Sylvanus Koui, Kouadio Donatien Koffi, Zie Cheick Traoré, Mohamed Kouyate

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Breast cancer is a heterogeneous and a hormone-dependent disease. The detection of the estrogen receptor (ER) and progesterone receptor (PgR) is crucial for prognostic evaluation and treatment choice of breast cancer for clinical practice. The purpose of this study was to evaluate the expression of the hormonal receptors, their distribution, and their correlation with clinicopathologic prognostic parameters for the improvement of the patients’ treatment in Ivory Coast.

Methods

The 20-month prospective study included 302 patients who were diagnosed with primary invasive breast carcinomas at the Central Laboratory in Abidjan. The paraffin-embedded blocks of these patients were examined by immunohistochemistry to assess the ER and PgR status. The one-way analysis of variance and Chi-Square Test were used to analyze the data.

Results

The mean age of patients at diagnosis was 48 ± 11 years. The majority of the women were premenopausal in 180 cases (59.9%). The predominant histologic type was invasive ductal carcinoma not otherwise specified (IDC NOS) in 247 cases (82%). Tumor grade 2 was more frequent in 166 cases (55%). Among 302 patients, 169 (56%) and 154 (49%) expressed ER and PgR respectively. The ER+PgR+ group with 131 cases (43%) was predominant, followed by 116 cases (38%) of ER-PgR-. The expression of ER and PgR was correlated with the age of the patients (p = 0.026) and the tumor grade (p = 0.0004). However, there was not statistically significant correlation between ER/PgR and the menopausal status of patients (p = 0.149), nor between ER/PgR and the histologic type (p = 0.523).

Conclusion

The ER+PgR+ and ER-PgR- are the most common subgroups in women with breast cancer in Ivory Coast. The hormonal receptor status is associated with the age and the histologic grade in breast cancer patients. The systematic use of hormonal treatment should be reevaluated. A further study should be done to investigate the reasons of high rate of ER-PgR- in breast cancer patients in Ivory Coast.
Literature
1.
American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
2.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRefPubMed
3.
4.
Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76(1):27–36.CrossRefPubMed
5.
Knight 3rd WA, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab. 1980;9(2):361–8.CrossRefPubMed
6.
Elwood JM, Godolphin W. Estrogen receptors in breast tumors: Association with age, menopausal status, and epidemiological and clinical features in 735 patients. Br J Cancer. 1980;42(5):635–44.CrossRefPubMedPubMedCentral
7.
Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21–7.CrossRefPubMed
8.
Osborne CK, Yochmowitz MG, Knight 3rd WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46 Suppl 12:2884–8.CrossRefPubMed
9.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.CrossRef
10.
Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori. 2008;94(3):370–83.PubMed
11.
Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, Lesperance ML. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol. 2004;22(9):1769–70.CrossRefPubMed
12.
Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005;23(4):931–2.CrossRefPubMed
13.
Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, Beck AH. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013;15(4):R68.CrossRefPubMedPubMedCentral
14.
McGuire WL, Horwitz KB, Pearson OH, Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer. 1977;39 Suppl 6:2934–47.CrossRefPubMed
15.
Barlett JM, Brookes CL, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2011;29:1531–8.CrossRef
16.
Didi-Kouko Coulibaly J, Effi AB, Horo GA, Diabate A, Mbra K, Adoubi I, et al. Hormonal status and overexpression of HER2 in breast cancer, Cancerology department of Treichville UHC. Preliminary results. Bull Cancer. 2008;95(9):799–803.PubMed
17.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.CrossRefPubMed
18.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedPubMedCentral
19.
Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, et al. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008;98:992–6.CrossRefPubMedPubMedCentral
20.
Effi AB, N’Dah KJ, N’Guiessan AA, Doukouré B, Kouyaté M, Abouna AD, et al. Epidemiology and histopathology of cancers in Ivory Coast. Afr J Cancer. 2012;4(1):41–7.CrossRef
21.
Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N. PyrhönenS, Collan Y. Prognostic value of proliferation markers: immunohistochemical Ki-67 expression and cytometric S-Phase Fraction of women with breast cancer in Libya. J Cancer. 2012;3:421–31.CrossRefPubMedPubMedCentral
22.
Fouad A, Yousra A, Kaoutar Z, Omar EM, Afaf A, Sanae B. Molecular Classification of breast cancer in Morocco. Pan Afr Med J. 2012;13:91.PubMedPubMedCentral
23.
Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Siddiqui N, et al. Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region. J Natl Compr Canc Netw. 2010;8 Suppl 3:S8–S15.PubMed
24.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–802.CrossRefPubMed
25.
Parkin DM, Vizcain AP, Skinner MEG, Ndhlovu A. Cancer patterns and risk factors in the African population of Southwestern Zimbabwe 1963-1977. Cancer Epidemiol Biomarkers Prev. 1994;3:537–47.PubMed
26.
Palmer JR, Wise LA, Horton NJ, et al. Dual effect of parity on breast cancer risk in African- American women. J Natl Cancer Inst. 2003;95:478–83.CrossRefPubMed
27.
Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1883–91.CrossRefPubMedPubMedCentral
28.
Li CI, Beaber EF, Tang M-TC, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. Breast Cancer Res Treat. 2013;137(2):579–87.CrossRefPubMed
29.
Loehberg CR, Almstedt K, Jud SM, Haeberle L, Fasching PA, Hack CC, et al. Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Res Treat. 2013;138(3):899–908.CrossRefPubMed
30.
Visscher DW, Zarbo RJ, Greenawald KA, Crissman JD. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. Pathol Annu. 1990;25:171–210.PubMed
31.
Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-reduced CK5 expression in metastases. Breast Cancer (Auckl). 2013;7:23–34.
32.
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–52.CrossRefPubMedPubMedCentral
33.
Ohene-Yeboah M, Adjei E. Breast cancer in Kumasi, Ghana. G M J. 2012;46(1):8–13.
34.
Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74:1445–51.CrossRefPubMedPubMedCentral
35.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2008;365:1687–717.
36.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23(30):7721–35.CrossRefPubMed
37.
38.
39.
Adeniji KA, Huo D, Khramtsov A, Zhang C, Olopade OI. Molecular profiles of breast cancer in Ilorin, Nigeria. J Clin Oncol. 2010;28:15s. 2010 (suppl; abstr 1602).
40.
Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24(7):1016–9.CrossRefPubMed
41.
Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120(1):86–92.CrossRefPubMed
Metadata
Title
Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast
Authors
Ahoua Benjamin Effi
Nguiessan Alphonse Aman
Baumaney Sylvanus Koui
Kouadio Donatien Koffi
Zie Cheick Traoré
Mohamed Kouyate
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3105-z

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Research article

Validation of an NGS mutation detection panel for melanoma

Research article

Multi-region and single-cell sequencing reveal variable genomic heterogeneity in rectal cancer

Research article

Cancer incidence in Germany attributable to human papillomavirus in 2013

Research article

The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

Research article

EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits